MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:45Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Thyroid hormones]]
			[[Category:Hormone replacement]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #220

2026-05-23T04:21:35Z

parser-claude batch MedTemplate pre-fill, Top 300 #220

New page

{{MedTemplate
| generic = Liothyronine (T3, triiodothyronine sodium)
| brand = Cytomel (oral), Triostat (IV)
| structure =
| classes = [[:Category:Thyroid_hormones|Thyroid hormone]], [[:Category:Hormone_replacement|Hormone replacement]]
| uses = <vote slug="hypothyroidism-T3-adjunct-use">Hypothyroidism (T3 supplement, selected refractory cases)</vote>, <vote slug="myxedema-coma-use">Myxedema coma (IV, in addition to T4)</vote>, <vote slug="thyroid-cancer-tsh-suppression-bridge-use">Bridge between T4 withdrawal and radioiodine scan/treatment in thyroid cancer</vote>
| starting_dose = Hypothyroidism: 5-25 mcg PO daily (start low, titrate slowly); myxedema coma: 5-20 mcg IV q4-12h with T4 loading
| preparations = 5, 25, 50 mcg tablets (Cytomel); 10 mcg/mL IV (Triostat)
| fda_max = 100 mcg/d typical
| pill_id =
| routes = Oral, IV
| onset = Hours (faster than T4); peak biologic activity 24-48 hours
| duration = 24-72 hours
| halflife = ~1 day (much shorter than T4's ~7 days)<ref name="cytomel-label">FDA Prescribing Information, Cytomel (liothyronine sodium), Pfizer/King, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/010379s055lbl.pdf</ref>
| bioavailability = ~95% (oral)<ref name="cytomel-label" />
| pregnancy = T4 (levothyroxine) is the first-line in pregnancy; T3 is rarely needed.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="liothyronine-mech-claim">Liothyronine is bioidentical T3 (triiodothyronine), the active thyroid hormone that binds nuclear thyroid hormone receptors with ~10× the affinity of T4; T4 (levothyroxine) is essentially a prodrug peripherally deiodinated to T3.</vote> Direct T3 supplementation bypasses peripheral deiodination, useful in myxedema coma (rapid clinical effect needed) and in some refractory hypothyroidism (combination T4+T3, controversial). Short half-life produces fluctuating serum levels with intermittent supraphysiologic peaks — one reason T4 monotherapy remains the practical standard<ref name="cytomel-label" />.
}}

== References ==
<references />

Liothyronine - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #220